A. A. Stefanenkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. A. Stefanenkova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Grushko
Federal State Budgetary Institution "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, St. Petersburg, Russia
1 shared publication - A. V. Kulish
S.M. Kirov Military Medical Academy, Ministry of Defense of Russia
1 shared publication - Denis V. Nesterov
Federal State Budgetary Institution "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, St. Petersburg, Russia
1 shared publication - E. S. Eniseeva
Irkutsk State Medical University
1 shared publication - E.V. Zagainov
Federal State Budgetary Institution "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, St. Petersburg, Russia
1 shared publication - Elena Yuryevna Bagadaeva
ГБУЗ «Иркутская ордена «Знак Почёта» областная клиническая больница», Иркутск
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 2 (3, Suppl. ) , onmt_A14
Comparison of the Sensitivity of CT-Arteriohepaticography and Intravenous Contrast-Enhanced CT in Colorectal Cancer Liver Metastases After Neoadjuvant Chemotherapy
Introduction: The main method for preoperative assessment of colorectal cancer (CRC) liver metastases remains intravenous contrast-enhanced computed tomography (CT); however, its sensitivity is limited, especially for lesions smaller than 10 mm, and neoadjuvant chemotherapy further reduces it. The characteristic CT appearance of a metastasis is hypodensity in the portal phase and a rim of enhancement at the lesion edge, which can be enhanced by injecting contrast material directly into the hepatic arteries. CT-arteriohepaticography (CT-AHG) is potentially more effective, including during drug treatment, but data on its sensitivity after chemotherapy are virtually absent. Objective: To compare the diagnostic efficacy of CT-AHG and intravenous contrast-enhanced CT in the detection and characterization of CRC liver metastases in patients after neoadjuvant chemotherapy. Materials and Methods: This single-center prospective study included 22 patients with CRC and liver metastases who underwent both imaging methods prior to liver resection at the N.N. Petrov National Medical Research Center of Oncology. The unit of analysis was the lesion. The reference standard was targeted histological examination of each resected lesion. CT and CT-AHG were evaluated independently, using animated images, by radiologists with more than 5 years of experience, one for each "patient–method" pair. For each method, sensitivity, specificity, and predictive values with 95% Clopper–Pearson confidence intervals (CIs) were calculated for 129 included lesions. The difference in sensitivities was reported with 95% CI (patient-level bootstrap) and tested using McNemar's exact test. Results: With combined use of CT and CT-AHG (a lesion was considered positive if detected by at least one method), sensitivity was 80.8% [72.6–87.4], which was 10.0 percentage points (95% CI: +2.4 to +17.9) higher than the sensitivity of CT alone. Individually, sensitivity was 70.8% [61.8–78.8] for CT and 73.3% [64.5–81.0] for CT-AHG. The difference between them was −2.5 percentage points (95% CI: −9.5 to +6.8) and was not statistically significant (p = 0.66). For lesions smaller than 10 mm, sensitivity was 35.3% for CT versus 50.0% for CT-AHG; for lesions 10 mm or larger, sensitivity was 84.9% and 82.6%, respectively. Conclusion: The sensitivity of CT-AHG does not differ significantly from that of intravenous contrast-enhanced CT; however, the combination of methods improves sensitivity by 10.0 percentage points. Therefore, CT-AHG should be considered as a complement to CT, rather than a replacement for it.
- 21 September 2026
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 2 (3, Suppl. ) , onmt_A14
Open AccessComparison of the Sensitivity of CT-Arteriohepaticography and Intravenous Contrast-Enhanced CT in Colorectal Cancer Liver Metastases After Neoadjuvant Chemotherapy
Introduction: The main method for preoperative assessment of colorectal cancer (CRC) liver metastases remains intravenous contrast-enhanced computed tomography (CT); however, its sensitivity is limited, especially for lesions smaller than 10 mm, and neoadjuvant chemotherapy further reduces it. The characteristic CT appearance of a metastasis is hypodensity in the portal phase and a rim of enhancement at the lesion edge, which can be enhanced by injecting contrast material directly into the hepatic arteries. CT-arteriohepaticography (CT-AHG) is potentially more effective, including during drug treatment, but data on its sensitivity after chemotherapy are virtually absent. Objective: To compare the diagnostic efficacy of CT-AHG and intravenous contrast-enhanced CT in the detection and characterization of CRC liver metastases in patients after neoadjuvant chemotherapy. Materials and Methods: This single-center prospective study included 22 patients with CRC and liver metastases who underwent both imaging methods prior to liver resection at the N.N. Petrov National Medical Research Center of Oncology. The unit of analysis was the lesion. The reference standard was targeted histological examination of each resected lesion. CT and CT-AHG were evaluated independently, using animated images, by radiologists with more than 5 years of experience, one for each "patient–method" pair. For each method, sensitivity, specificity, and predictive values with 95% Clopper–Pearson confidence intervals (CIs) were calculated for 129 included lesions. The difference in sensitivities was reported with 95% CI (patient-level bootstrap) and tested using McNemar's exact test. Results: With combined use of CT and CT-AHG (a lesion was considered positive if detected by at least one method), sensitivity was 80.8% [72.6–87.4], which was 10.0 percentage points (95% CI: +2.4 to +17.9) higher than the sensitivity of CT alone. Individually, sensitivity was 70.8% [61.8–78.8] for CT and 73.3% [64.5–81.0] for CT-AHG. The difference between them was −2.5 percentage points (95% CI: −9.5 to +6.8) and was not statistically significant (p = 0.66). For lesions smaller than 10 mm, sensitivity was 35.3% for CT versus 50.0% for CT-AHG; for lesions 10 mm or larger, sensitivity was 84.9% and 82.6%, respectively. Conclusion: The sensitivity of CT-AHG does not differ significantly from that of intravenous contrast-enhanced CT; however, the combination of methods improves sensitivity by 10.0 percentage points. Therefore, CT-AHG should be considered as a complement to CT, rather than a replacement for it.
- Open Access
- 24 September 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 9,p. 45-47
Radiation heart disease in a patient post treatment of Нodgkin’s lymphoma
A clinical case of radiation induced heart disease in 43 year old female patient after 15 years since radiation therapy of Hodgkin’s lymphoma. During clinical and instrumental investigation, a post-radiation constrictive pericarditis was found, comorbid with lesion of aortic, mitral and tricuspid valves. Surgical treatment of pericarditis was applied. Morphology confirmed the diagnosis.
- 24 September 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 9,p. 45-47
Open AccessRadiation heart disease in a patient post treatment of Нodgkin’s lymphoma
A clinical case of radiation induced heart disease in 43 year old female patient after 15 years since radiation therapy of Hodgkin’s lymphoma. During clinical and instrumental investigation, a post-radiation constrictive pericarditis was found, comorbid with lesion of aortic, mitral and tricuspid valves. Surgical treatment of pericarditis was applied. Morphology confirmed the diagnosis.